Covid-19. To develop and progress HDT-301, a replicon RNA encoding sars-COV-2 spike protein bound to lipid inorganic nanoparticle (LION) formulation to protect against covid-19, through a phase I…
Ended Definitive Contract Awarded Last action
- Contract number
- 75N93020C00052
- Awardee
-
HDT Bio Corp UEI Z33DCMWXZBK7
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $10,970,058
Award facts
- Opportunity
-
- 2020 NIAID Omnibus Broad Agency Announcement Pre-Solicitation · HHSNIHNIAIDBAA20201 · Posted Dec 11, 2019
- COVID-19: HHS-NIH-NIAID-BAA2020-1: Research Area 003, Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases Award Notice · Posted Aug 21, 2020
- 2020 NIAID Omnibus Broad Agency Announcement Solicitation · Posted Jan 3, 2020
- Contract value 100% obligated
- $10,970,058.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- PSC
- AJ12 General Science And Technology R&D Services; General Science And Technology; Applied Research
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 9 offers Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Seattle, WA 98102, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $2,717,614 | |
| Exercise an Option | $4,015,904 | |
| Original award | $4,236,540 |
About this award
HDT Bio Corp. was awarded a $11 million cost-plus-fixed-fee definitive contract by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to develop and progress HDT-301, a replicon RNA encoding SARS-CoV-2 spike protein bound to lipid inorganic nanoparticle formulation, through a Phase I clinical trial. The contract was awarded under the 2020 NIAID Omnibus Broad Agency Announcement seeking proposals to develop medical countermeasures including vaccines, therapeutics, diagnostics and radiation countermeasures across five research areas. Work will be performed in Seattle, Washington over a four year period ending in June 2024 to address needs under the NIAID program. No set aside designation or major subcontractors were identified.
Description
Covid-19. To develop and progress HDT-301, a replicon RNA encoding sars-COV-2 spike protein bound to lipid inorganic nanoparticle (LION) formulation to protect against covid-19, through a phase I clinical trial.
Quick answers
Who was awarded contract 75N93020C00052?
75N93020C00052 was awarded to HDT Bio Corp by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 1, 2020.
How much is contract 75N93020C00052 worth?
The government has obligated $10,970,058 on 75N93020C00052.
Was contract 75N93020C00052 competed?
The extent of competition for 75N93020C00052 was full and open competition. The government received 9 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award